Holkova, B., Perkins, E. B., Ramakrishnan, V., Tombes, M. B., Shrader, E., Talreja, N., . . . Grant, S. (2011). Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-cell Neoplasms.
シカゴスタイル引用形Holkova, Beata, et al. Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients With Recurrent or Refractory B-cell Neoplasms. 2011.
MLA引用形式Holkova, Beata, et al. Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients With Recurrent or Refractory B-cell Neoplasms. 2011.
警告: この引用は必ずしも正確ではありません.